Travere Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TVTX | MAZE | DNLI | NEU.AX | BBIO | MIRM | |
|---|---|---|---|---|---|---|
| Market cap | 5.03B | 1.85B | 3.35B | 2.95B | 15.17B | 6.30B |
| P/E (TTM) | — | — | — | 154.9 | — | — |
| Forward P/E | 9.9 | -10.5 | -8.9 | 38.9 | -225.0 | -570.4 |
| Price/book | 222.1 | 4.1 | 3.6 | 8.8 | -5.9 | 16.0 |
| Dividend yield | — | — | — | 1.52% | — | — |
| 1-year change | +57.42% | +12.66% | +45.45% | −2.22% | +24.17% | +24.17% |
| Today | +6.09% | +3.50% | +7.76% | +17.49% | +5.21% | +11.42% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All TVTX news ›Travere Therapeutics to Participate at Upcoming November 2026 Investor Conferences
Guggenheim Global Healthcare ConferencePresenting on Tuesday, November 10, 2026, at 8:00 a.m. ET Stifel 2026 Healthcare ConferencePresenting on Wednesday, November 11, 2026, at 3:20 p.m. ET UBS Global Biopharma ConferencePresenting on…
Travere Therapeutics, Inc. Stock 12‑Month Price Target Cut to $73.71, Implies 50% Upside
TradingView Travere Therapeutics, Inc. Stock 12‑Month Price Target Cut to $73.71, Implies 50% Upside - According to estimates from 14 analysts, Travere Therapeutics, Inc. stock's average price target has fallen
Aquestive Therapeutics GAAP EPS of -$0.18 misses by $0.06, revenue of $7.5M misses by $3.52M
Aquestive Therapeutics Q3 earnings missed on EPS and revenue as losses widened. - Aquestive Therapeutics press release (AQST): Q3 GAAP EPS of -$0.18 misses by $0.06. - Revenue of $7.5M (-41.5% Y/Y) misses by $3.52M.
Travere targets $3B FILSPARI sales by 2033 as patent terms extend into 2037
Travere Therapeutics Q3 2026 earnings: FILSPARI sales topped $200M, patent runway extended to 2037, and Q4 headwinds loom. Earnings Call Insights: Travere Therapeutics (TVTX) Q3 2026 - Dr. Eric Dube said the quarter reflected “excellent…
Travere Therapeutics Non-GAAP EPS of -$0.31 misses by $0.73, revenue of $224.5M beats by $29.21M
Travere Therapeutics Q3 results: revenue beat on 36% growth, but EPS missed as R&D and SG&A rose. - Travere Therapeutics press release (TVTX): Q3 Non-GAAP EPS of -$0.31 misses by $0.73. - Revenue of $224.5M (+36.1% Y/Y) beats by $29.21M. -…
Travere Therapeutics, Inc. Announces CEO Changes, Effective December 1, 2026
On September 21, 2026, Travere Therapeutics, Inc. and Eric Dube, Ph.D., mutually agreed to the timeline and terms surrounding the planned transition of Dr. Dube, who will step down from his position... On September 21, 2026, Travere…
Travere Therapeutics Receives Notice Of Allowance From The U.S. Patent And Trademark Office For U.S. Patent Application Directed To Certain Methods Of Using FILSPARI In Focal Segmental Glomerulosclerosis
Travere Therapeutics, Inc. announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled ?Biphenyl Sulfonamide Compounds... announced that the United States…
Travere Therapeutics President and CEO Eric Dube Plans to Step Down
Travere Therapeutics said late Monday its president and chief executive officer Eric Dube has decided to step down to focus on his health and family. The board has unanimously selected Bradley... Biotechnology & Medical Research Travere…
Financial Comparison: BioNTech (NASDAQ:BNTX) & Travere Therapeutics (NASDAQ:TVTX)
Posted by Sarita Garza on Oct 27th, 2026 BioNTech (NASDAQ:BNTX – Get Free Report) and Travere Therapeutics (NASDAQ:TVTX – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies…
TRT Kingdom Highlights Dedicated Transfer Pathway for Patients Switching TRT Providers
The "Switch to Kingdom" process of Switching your TRT Provider combines secure records submission, a dedicated transfer coordinator and consultation with a licensed provider. Patients can submit recent laboratory results, current…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com7
- seekingalpha.com5
- stocktitan.net4
- biospace.com2
- themarketsdaily.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 25 articles, not a forecast.